سعر نوفوسيفن 1.2 مجم فيال 2026

NovoSeven 1.2 mg powder for solution for IV injection (recombinant coagulation factor VIIa); Egyptian listing.

• Treatment of bleeding episodes and prevention of bleeding in surgical interventions or invasive procedures in patients with hemophilia A or B with inhibitors to factor VIII or IX; congenital FVII deficiency; Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions (per US NovoSeven RT label — confirm Egyptian licensed indications).Population: Per US label populationsDailyMed / FDA

• Thrombosis, fever, injection-site reaction, hypertension, hypersensitivity, decreased therapeutic response.International label, same formulation · DailyMed / FDA

• Hypersensitivity to NovoSeven RT, any of its components, or to mouse, hamster, or bovine proteins (US label).International label, same formulation · DailyMed / FDA

• Serious arterial and venous thrombotic and thromboembolic events have been reported; monitor patients with risk factors. Hypersensitivity reactions including anaphylaxis may occur.International label, same formulation · DailyMed / FDA

• Limited available data in pregnant women are insufficient to inform a drug-associated risk; use only if clearly needed (US label).International label, same formulation · DailyMed / FDA

• Eptacog alfa (recombinant coagulation factor VIIa): Promotes haemostasis by activating the extrinsic pathway of the coagulation cascade; generates thrombin even when factors VIII or IX are inhibited.